Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

China flag China · Delayed Price · Currency is CNY
10.34
+0.06 (0.58%)
At close: Dec 5, 2025
-21.01%
Market Cap 23.06B
Revenue (ttm) 4.74B
Net Income (ttm) 935.80M
Shares Out 2.23B
EPS (ttm) 0.42
PE Ratio 24.75
Forward PE 26.18
Dividend 0.27 (2.62%)
Ex-Dividend Date Jun 10, 2025
Volume 8,091,957
Average Volume 9,652,576
Open 10.28
Previous Close 10.28
Day's Range 10.17 - 10.35
52-Week Range 10.14 - 14.74
Beta 0.12
RSI 34.06
Earnings Date Apr 20, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; urso... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 3,184
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301301
Full Company Profile

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.

Financial Statements

News

There is no news available yet.